Menu Back toPatient-Focused-Medicines-Development-Where-It-has-Led-us-to-Today-What-Challenges-Remain-and-What-Do-we-Still-Need-to-do-to-Achieve-Success

DIA 2018 Global Annual Meeting

Patient-Focused Medicines Development: Where It has Led us to Today, What Challenges Remain, and What Do we Still Need to do to Achieve Success?

    Session Chair(s)
      Veronica L. Todaro, MPH

      Veronica L. Todaro, MPH

      • Vice President, National Programs
      • Parkinson's Foundation, United States
    Using a multi-disciplinary approach, we will take a dynamic look at the experience of those involved in patient engagement, across stakeholder groups representing different regions, to understand how we have collectively moved the needle. As organizations have embarked upon efforts and implemented initiatives, we will provide a bird’s eye view of the impact of patient engagement across various stakeholders.
    Learning Objective : Describe how patient engagement has evolved across stakeholder groups in the past few years Discuss the impact of collective approaches on patient engagement in medicines development lifecycle Apply key learnings from collective approaches in their own efforts Describe recent achievements in patient engagement and identify remaining challenges
      Sarah  Krug, MS, MSc

      What Remains to be Done to Deliver Patient-Focused Medicines: Where Do We Go From Here? How Can We collaboratively Build on What We Know

      Sarah Krug, MS, MSc

      • CEO
      • CANCER101, United States